From CNBC: 2024-12-24 07:00:02

In New York City on Dec. 11, 2023, Eli Lilly’s weight loss drug Zepbound, priced at $1,000 per month, was showcased. Willow Baillies, unable to afford Zepbound, opted for a cheaper compounded version of tirzepatide, the active ingredient. The FDA announced the end of the branded tirzepatide shortage, limiting access to compounded versions.

Compounded versions of tirzepatide may soon be unavailable due to FDA actions, affecting patients like Baillies. Some may stockpile doses, switch treatments, or cease care due to financial constraints. Eli Lilly’s efforts to increase manufacturing of tirzepatide have paid off, improving access for patients with insurance coverage.

Patients like Bonello and Hunt, reliant on compounded tirzepatide, are concerned about maintaining care amid the shortage resolution. Some may switch to branded versions or explore alternatives. The legal battle between the FDA and compounding pharmacies further complicates the situation, leaving patients unsure of their future access to medications.



Read more at CNBC: FDA Zepbound shortage ends, impacts patients, compounding pharmacies